CO2023015125A2 - Formulación compuesta para administración oral que comprende ácido 1-(3-ciano-1-isopropil-indol-5-il)pirazol-4-carboxílico - Google Patents

Formulación compuesta para administración oral que comprende ácido 1-(3-ciano-1-isopropil-indol-5-il)pirazol-4-carboxílico

Info

Publication number
CO2023015125A2
CO2023015125A2 CONC2023/0015125A CO2023015125A CO2023015125A2 CO 2023015125 A2 CO2023015125 A2 CO 2023015125A2 CO 2023015125 A CO2023015125 A CO 2023015125A CO 2023015125 A2 CO2023015125 A2 CO 2023015125A2
Authority
CO
Colombia
Prior art keywords
oral administration
compound formulation
api
particle size
indol
Prior art date
Application number
CONC2023/0015125A
Other languages
English (en)
Inventor
Seok Cheol Yoo
Joomyung Jang
Jin A Seo
Dohyung Lim
Original Assignee
Lg Chemical Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lg Chemical Ltd filed Critical Lg Chemical Ltd
Publication of CO2023015125A2 publication Critical patent/CO2023015125A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Inorganic Chemistry (AREA)
  • Urology & Nephrology (AREA)

Abstract

La presente invención se refiere a una formulación compuesta para administración oral que comprende un principio activo farmacéutico (API) seleccionados de ácido 1-(3-ciano-1-isopropil-indol-5-il)pirazol-4-carboxílico o una sal farmacéuticamente aceptable de este, donde el API tiene un tamaño de partícula de gránulos que corresponda al 90% del tamaño máximo de partícula en la distribución acumulativa del tamaño de partículas (D(0,9)) de 80 μm o más y de 300 μm o menos. La formulación compuesta para administración oral según la presente invención tiene una baja friabilidad y una mayor velocidad de disolución incluso si se incluye un contenido elevado de API, ajustando el tamaño de partícula del API a un cierto intervalo.
CONC2023/0015125A 2021-04-16 2023-11-07 Formulación compuesta para administración oral que comprende ácido 1-(3-ciano-1-isopropil-indol-5-il)pirazol-4-carboxílico CO2023015125A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20210049613 2021-04-16
PCT/KR2022/005451 WO2022220636A1 (ko) 2021-04-16 2022-04-15 1-(3-시아노-1-아이소프로필-인돌-5-일)피라졸-4-카르복실산을 포함하는 경구용 제제

Publications (1)

Publication Number Publication Date
CO2023015125A2 true CO2023015125A2 (es) 2023-11-20

Family

ID=83640832

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2023/0015125A CO2023015125A2 (es) 2021-04-16 2023-11-07 Formulación compuesta para administración oral que comprende ácido 1-(3-ciano-1-isopropil-indol-5-il)pirazol-4-carboxílico

Country Status (14)

Country Link
EP (1) EP4324459A1 (es)
JP (1) JP2024511899A (es)
KR (1) KR102585644B1 (es)
CN (1) CN117136049A (es)
AR (1) AR125366A1 (es)
AU (1) AU2022257531A1 (es)
BR (1) BR112023021236A2 (es)
CA (1) CA3213929A1 (es)
CL (1) CL2023002970A1 (es)
CO (1) CO2023015125A2 (es)
MX (1) MX2023011500A (es)
PE (1) PE20240764A1 (es)
TW (1) TW202245755A (es)
WO (1) WO2022220636A1 (es)

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0810524B8 (pt) * 2007-04-11 2021-05-25 Kissei Pharmaceutical derivado de (aza)indol, inibidor de xantina oxidase e composição farmacêutica compreendendo o dito derivado
WO2008134557A2 (en) * 2007-04-25 2008-11-06 Teva Pharmaceutical Industries Ltd. Solid dosage forms
TWI423962B (zh) * 2009-10-07 2014-01-21 Lg Life Sciences Ltd 有效作為黃嘌呤氧化酶抑制劑之新穎化合物、其製備方法及含該化合物之醫藥組成物
TWI548630B (zh) * 2011-04-06 2016-09-11 Ｌｇ生命科學有限公司 １－（３－氰基－１－異丙基－吲哚－５－基）吡唑－４－羧酸結晶型及其製造方法
KR101399514B1 (ko) * 2013-10-28 2014-05-27 에스케이케미칼주식회사 폴라프레징크를 함유하는 안정한 정제 제형
CN106008488B (zh) * 2016-05-20 2018-10-30 广东东阳光药业有限公司 氰基吲哚类衍生物及其制备方法和用途
KR102297480B1 (ko) 2019-10-25 2021-09-02 서울대학교산학협력단 비정형 질문 또는 요구 발화의 구조화된 패러프레이징 시스템 및 방법

Also Published As

Publication number Publication date
WO2022220636A1 (ko) 2022-10-20
MX2023011500A (es) 2023-10-04
KR102585644B1 (ko) 2023-10-06
PE20240764A1 (es) 2024-04-17
AU2022257531A1 (en) 2023-10-26
BR112023021236A2 (pt) 2023-12-12
AR125366A1 (es) 2023-07-12
CA3213929A1 (en) 2022-10-20
TW202245755A (zh) 2022-12-01
CN117136049A (zh) 2023-11-28
JP2024511899A (ja) 2024-03-15
CL2023002970A1 (es) 2024-03-15
KR20220143593A (ko) 2022-10-25
EP4324459A1 (en) 2024-02-21

Similar Documents

Publication Publication Date Title
JP6774435B2 (ja) 抗ウイルス活性を有する鼻づまり解除組成物
RU2495662C2 (ru) Антимикробные композиции с контролируемым высвобождением для лечения ушных заболеваний
AU2013266067B2 (en) Xylitol-based anti-mucosal compositions and related methods and compositions
GB0814302D0 (en) Compounds and methods
US20110281901A1 (en) Pharmaceutical compositions and methods of making same
HRP20211686T1 (hr) Formulacije intravenozne otopine sa posakonazolom, stabilizirane supstituiranim beta-ciklodekstrinom
JP2024028490A (ja) ロキソプロフェンを含有する医薬組成物＜陸＞
ES2834985T3 (es) Composición que contiene cineol para administración nasal
JP2021120419A (ja) ロキソプロフェンを含有してなる医薬製剤（弐）
EA202090029A1 (ru) Твердая композиция карипразина для орального введения
JP2006219482A (ja) 掻痒抑制剤
ES2548706T3 (es) Nanosuspensión farmacéutica
RU2701514C2 (ru) Антивирусная фармацевтическая композиция
HU230738B1 (hu) Ketotifén tartalmú szemészeti készítmény
CO2023015125A2 (es) Formulación compuesta para administración oral que comprende ácido 1-(3-ciano-1-isopropil-indol-5-il)pirazol-4-carboxílico
JP2019081755A (ja) 組成物
KR20190025810A (ko) 안과용 제품 및 점도 저하 억제 방법
JP6213715B2 (ja) 多成分配合点眼剤
JP6844394B2 (ja) 固形組成物
ES2782898T3 (es) Métodos de administración de compuestos agonistas de la trombopoyetina
JP5299449B2 (ja) 外用剤組成物
JP5627235B2 (ja) 眼科用組成物
JP5565995B2 (ja) 鎮痒剤
JP2005035969A (ja) 眼科用組成物及び該組成物の安定化方法
JP2005206523A (ja) 外用鎮痒剤